Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CICR-NAM in Healthy Subjects and IBD Patients
NCT05258474Phase 1Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nicotinamide in inflammatory bowel disease (IBD) (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Treatment-Emergent Adverse Events up to 60 days, Treatment-Emergent Serious Adverse Events up to 60 days and 9 more. Started Dec 2020; status: completed.
02
Drugs
nicotinamide
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05258474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258474.